Are drug-eluting stents superior to bare-metal stents in
patients with unprotected non-bifurcational left main
disease? Insights from a multicentre registry
by Corrado Tamburino, Maria Elena Di Salvo, Davide Capodanno, Antonio
Marzocchi, Imad Sheiban, Massimo Margheri, Aleardo Maresta, Fabio Barlocco,
Giuseppe Sangiorgi, Giancarlo Piovaccari, Antonio Bartorelli, Carlo Briguori, Diego
Ardissino, Francesco Di Pede, Angelo Ramondo, Luigi Inglese, Anna Sonia Petronio,
Leonardo Bolognese, Alberto Benassi, Cataldo Palmieri, Aldo Patti, and Stefano De
Servi
EHJ
Volume 30(10):1171-1179
May 14, 2009
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author
2009. For permissions please email: [email protected]
Actuarial rate of survival (A), survival free from cardiac death (B), target lesion revascularization
(TLR) (C), and major adverse cardiovascular events (MACE) (D) at 3 years among patients who
received drug-eluting stents or bare-metal stents.
Corrado Tamburino et al. Eur Heart J 2009;30:1171-1179
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author
2009. For permissions please email: [email protected]